Olaparib: A Treatment for Advanced Ovarian and Breast Cancer

Introduction to Olaparib

Olaparib, marketed under the name Lynparza, is a therapeutic option for patients with advanced ovarian cancer who have inherited mutations in the BRCA gene. Recent studies have also investigated the effectiveness of olaparib compared to standard therapies for treating metastatic breast cancer in patients with inherited BRCA mutations.

Understanding BRCA Mutations

Mutations in the BRCA1 and BRCA2 genes, which are crucial for DNA repair, significantly increase the risk of developing breast cancer. Individuals with germline mutations in BRCA1 often present at a younger age, frequently have a familial history of the disease, and may be classified as triple-negative for key cell surface proteins: HER2, estrogen receptor, and progesterone receptor.

Current Indications for Olaparib

Olaparib is currently approved for managing recurrent ovarian cancer in patients with germline BRCA mutations. Additionally, emerging evidence suggests that olaparib is also effective in treating metastatic breast cancer patients carrying the same mutation. Ongoing clinical trials are exploring its efficacy in various cancer types.

Recent Study on Olaparib for Metastatic Breast Cancer

Study Overview

A phase III open-label trial recently published in the New England Journal of Medicine examined the efficacy of olaparib in advanced metastatic breast cancer patients with germline BRCA mutations. The study was sponsored by AstraZeneca and included 302 adult participants who were randomly assigned to either the olaparib group (205 participants) or the standard-therapy group (97 participants, with 91 receiving treatment).

Patient Selection Criteria

Eligible patients had metastatic breast cancer that was either triple-negative or HER2-negative, with estrogen and/or progesterone receptor positivity. Participants also had to possess a deleterious germline BRCA mutation and had previously undergone no more than two chemotherapy regimens for metastasis. Furthermore, they needed to demonstrate normal organ and bone marrow function, along with at least one tumor lesion suitable for response assessment.

Treatment Methodology

Patients in the olaparib group received oral doses of 300-milligram tablets twice daily. In contrast, the standard therapy group received one of three treatments: capecitabine (oral), eribulin mesylate (intravenous), or vinorelbine (intravenous). Treatment continued until disease progression or intolerable toxicity occurred.

Primary Endpoints and Results

The primary endpoint monitored was progression-free survival, defined as the period from baseline until disease progression (as determined by imaging tests) or patient death. The results indicated a median survival time of 7 months for patients treated with olaparib versus 4.2 months for those receiving standard therapy. Notably, the risk of death or disease progression was reduced by 42% among patients treated with olaparib. The treatment response rate was also significantly higher in the olaparib group at 59.9%, compared to 28.8% in the standard therapy group. Adverse events were generally less severe with olaparib, with nausea and anemia being the most common side effects.

Limitations and Future Implications

A key limitation of the trial was its open-label design. However, data analysis was conducted with blinded reviewers who were unaware of the treatment assignments. The findings provide optimism for triple-negative breast cancer patients facing limited treatment options after anthracycline and taxane therapies, as approximately 80% of breast cancers with BRCA1 mutations are triple-negative. Consequently, olaparib and similar PARP inhibitors may emerge as significant treatment avenues for this breast cancer subtype.

Conclusion

In conclusion, olaparib presents a promising treatment option for patients with advanced breast cancer harboring BRCA mutations, potentially expanding therapeutic choices for this challenging disease.

References

1. Kaufman B, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244-50.
2. Tutt A, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376(9737):235-44.
3. Clinical Studies involving Olaparib. ClinicalTrials.gov.
4. Robson M, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-33.